Active Recombinant Human CD200R1 protein, Fc-Avi-tagged, Biotinylated
|Product Overview :||Biotinylated Recombinant Human CD200R1(Ala27-Leu266) protein, carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag, was expressed in CHO cells.|
- Gene Information
- Related Products
|Description :||Cluster of Differentiation-200 receptor 1 (CD200R1), also known as OX-2 receptor, is a transmembrane protein in the immunoglobulin superfamily expressed on the surface of myeloid cells and important in the regulation of myeloid cell activity (1-3). Mature CD200R1 consists of an extracellular domain (ECD) with one Ig-like V‑type and one Ig-like C2-type domain, a transmembrane segment, and a short cytoplasmic domain (4). Despite lacking a cytoplasmic ITIM domain, CD200R1 has still been shown to propagate inhibitory signals (5, 6). Within the ECD, human CD200R1 shares 56% amino acid (aa) sequence identity with both mouse and rat CD200R1. Alternate splicing of the human CD200R1 mRNA generates four isoforms, two of which are truncated in the Ig-C2 domain and are likely secreted (4). Additionally, a separate CD200R gene encodes 1 protein in humans and 4 in mouse with high aa sequence identity with CD200R1 which are potentially activating receptors by means of their association with DAP12 (7, 8). CD200R1 expression is restricted primarily to mast cells, basophils, macrophages, and dendritic cells (9‑11) while its ligand, CD200, is widely distributed (12). Association of CD200 with CD200R1 takes place between their respective N-terminal Ig-like domains (13). Disruption of this receptor-ligand system by knockout of the CD200 gene in mice leads to increased macrophage number and activation and predisposition to autoimmune disorders (12). CD200R1 signaling inhibits the expression of proinflammatory molecules including TNFs, IFNs, and inducible nitric oxide synthase in response to selected stimuli, which implicate that CD200/CD200R1 inhibitory signaling pathway plays a prominent role in limiting inflammation in a wide range of inflammatory diseases (14). Further, the CD200/CD200R inhibitory signaling constitutes one of the most suitable endogenous immunoregulatory molecule candidate to restore the immune suppressive status of the CNS altered in chronic neuroinflammatory situations (15). Our Avi-tag Biotinylated CD200R1 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.|
|Source :||CHO cells|
|Predicted N Terminal :||Ala27|
|Form :||Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.|
|Bio-activity :||The biotin to protein ratio is greater than 0.7 as determined by the HABA assay. Recombinant Human CD200 is immobilized at 0.5 μg/mL(100 μL/well), the concentration that produces 50% of the optimal binding response is approximately 2.5-15 ng/mL.
Measured by its binding ability in a functional ELISA.
When Recombinant Human CD200 Fc Chimerais immobilized at 0.5 μg/mL (100 μL/well), the concentration of Biotinylated Recombinant Human CD200R1 Fc Chimera Avi-tag that produces 50% of the optimal binding response is appoximately 2.5-15 ng/mL.
|Molecular Mass :||80-100 kDa, under reducing conditions|
|Protein length :||Ala27-Leu266|
|Endotoxin :||<0.10 EU per 1 μg of the protein by the LAL method.|
|Purity :||>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.|
|Storage :||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 °C as supplied.1 month, 2 to 8 °C under sterile conditions after reconstitution.3 months, -20 to -70 °C under sterile conditions after reconstitution.|
|Reconstitution :||Reconstitute at 250 μg/mL in PBS.|
|Gene Name :||CD200R1 CD200 receptor 1 [ Homo sapiens ]|
|Official Symbol :||CD200R1|
|Synonyms :||CD200R1; CD200 receptor 1; MOX2 receptor , MOX2R; cell surface glycoprotein CD200 receptor 1; CD200R; HCRTR2; OX2R; MOX2 receptor; CD200 cell surface glycoprotein receptor; cell surface glycoprotein OX2 receptor 1; cell surface glycoprotein receptor CD200; MOX2R;|
|Gene ID :||131450|
|mRNA Refseq :||NM_138806|
|Protein Refseq :||NP_620161|
|UniProt ID :||Q8TD46|
|◆ Recombinant Protein|
|CD200R1-3057H||Recombinant Human CD200R1 Protein, MYC/DDK-tagged||+Inquiry|
|Cd200r1-125M||Recombinant Mouse Cd200r1 Protein, His (Fc)-Avi-tagged||+Inquiry|
|Cd200r1-661M||Recombinant Mouse Cd200r1 Protein, His-tagged||+Inquiry|
|CD200R1-3483C||Active Recombinant Cynomolgus CD200R1 Protein, His-tagged||+Inquiry|
|CD200R1-898R||Recombinant Rat CD200R1 Protein, His (Fc)-Avi-tagged||+Inquiry|
|CD200R1-2483CCL||Recombinant Cynomolgus CD200R1 cell lysate||+Inquiry|
|CD200R1-2523HCL||Recombinant Human CD200R1 cell lysate||+Inquiry|
|CD200R1-2226MCL||Recombinant Mouse CD200R1 cell lysate||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (7)Ask a question
Modulating CD200R1 signaling holds therapeutic potential for immune-related disorders. Enhancing CD200R1 signaling or agonizing CD200R1 with specific agonists could help dampen excessive immune responses, attenuate inflammation, and promote immune tolerance. Conversely, inhibiting CD200R1 signaling or blocking CD200-CD200R1 interaction may be beneficial in conditions where immune suppression is desired, such as cancer immunotherapy. However, further research is needed to develop safe and effective therapeutic strategies targeting CD200R1, taking into consideration the potential impact on immune cell functions and overall immune homeostasis.
Dysregulation of CD200R1 signaling has been implicated in the pathogenesis of several diseases. Reduced CD200R1 expression or impaired CD200-CD200R1 interaction has been observed in autoimmune disorders, such as multiple sclerosis and rheumatoid arthritis. This dysregulation can lead to excessive activation of immune cells and chronic inflammation. Furthermore, altered CD200R1 expression has been reported in neuroinflammatory conditions, such as Alzheimer's disease and Parkinson's disease. However, more studies are required to elucidate the specific roles of CD200R1 dysregulation in disease development and progression.
CD200R1 (CD200 receptor 1) is primarily expressed on the surface of various immune cells, including macrophages, dendritic cells, and mast cells. It is also found on some non-immune cells, such as neurons. The specific cellular localization of CD200R1 allows it to interact with its ligand, CD200, which is expressed on many cell types, including neurons, endothelial cells, and immune cells. This interaction plays a crucial role in regulating immune responses and maintaining immune homeostasis.
CD200R1 plays a critical role in immune regulation and tolerance. The interaction between CD200R1 on immune cells and its ligand CD200 on target cells provides a potent inhibitory signal, suppressing immune cell activation and effector functions. This regulation helps prevent autoimmune responses and excessive inflammation. CD200R1 signaling inhibits the activation of immune cells, such as macrophages and dendritic cells, thereby reducing their pro-inflammatory cytokine production and antigen presentation capacity. Dysregulation of CD200R1 signaling has been associated with autoimmune diseases and neuroinflammatory disorders.
CD200R1 expression is regulated by various factors, including cytokines and transcriptional regulators. Pro-inflammatory cytokines, such as interferon-gamma, can downregulate CD200R1 expression on immune cells, whereas anti-inflammatory cytokines, such as interleukin-4, can upregulate its expression. Transcription factors, such as PU.1 and GATA-1, are involved in regulating CD200R1 gene expression. Additionally, epigenetic modifications, such as DNA methylation and histone acetylation, can influence CD200R1 expression levels. Further research is needed to fully understand the complex regulatory mechanisms governing CD200R1 expression.
CD200R1 engagement with its ligand CD200 triggers inhibitory signaling pathways, primarily mediated by immunoreceptor tyrosine-based inhibitory motifs (ITIMs) present in the CD200R1 cytoplasmic domain. Upon ligand binding, CD200R1 recruits and activates phosphatases, such as SHP-1 and SHP-2, which dephosphorylate downstream signaling molecules. This leads to the inhibition of various immune cell functions, including phagocytosis, cytokine production, and antigen presentation. The CD200R1-CD200 signaling axis is crucial for maintaining immune tolerance and preventing excessive immune activation.
Upon binding of CD200 to CD200R1, several downstream signaling pathways are activated. One of the main pathways involves the recruitment and activation of Src homology 2 domain-containing protein tyrosine phosphatase (SHP)-1 and SHP-2. These phosphatases inhibit signaling cascades initiated by immune receptors, including inhibitory signaling through the inhibitory receptor CD200R1 itself. Additionally, CD200R1 engagement can also lead to the modulation of PI3K-Akt and MAPK pathways, further influencing immune cell function and cytokine production.
Customer Reviews (3)Write a review
The convenience it offers saves a considerable amount of time and effort. -
The robustness of this reagent guarantees consistent results, regardless of the number of experiment replications. -
Purity personified, unlocking the gates to triumphant experiments. -
Ask a Question for All CD200R1 Products
Required fields are marked with *
My Review for All CD200R1 Products
Required fields are marked with *